SCHEMBL24765181

SCHEMBL24765181

Cn1c(=O)n(C2CCC(=O)NC2=O)c2ccc(COC3CCN(C4CCNCC4)CC3)cc21

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 15/20 0.58
DDB1 Q16531 14/20 0.58
IKZF2 Q9UKS7 1/20 0.36
SLC6A4 P31645 2/20 0.34
SLC6A2 P23975 1/20 0.34
HTR2A P28223 1/20 0.34
HTR2C P28335 1/20 0.34
HTR7 P34969 1/20 0.34
HTR2B P41595 1/20 0.34
HTR3A P46098 1/20 0.34
SLC6A3 Q01959 1/20 0.34
HTR4 Q13639 1/20 0.34
CYP2D6 P10635 1/20 0.33
HRH3 Q9Y5N1 1/20 0.33
DRD2 P14416 1/20 0.32
IKZF3 Q9UKT9 1/20 0.32
PIK3CA P42336 1/20 0.32
PRKDC P78527 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24764192 0.92 DDB1 (0.66) CRBNDDB1SLC6A4SLC6A2HTR2A
SCHEMBL24765168 0.92 CRBN (0.57) CRBNDDB1IKZF2SLC6A4DRD2
Hydrochloric Acid SCHEMBL30042194 0.91 CRBN (0.56) CRBNDDB1IKZF2SLC6A4DRD2
SCHEMBL26635094 0.87 CRBN (0.61) CRBNDDB1IKZF2SLC6A4DRD2
SCHEMBL26634926 0.85 CRBN (0.61) CRBNDDB1IKZF2SLC6A4DRD2
SCHEMBL24764247 0.84 CRBN (0.58) CRBNDDB1IKZF2SLC6A4DRD2
SCHEMBL24764242 0.84 CRBN (0.58) CRBNDDB1IKZF2PIK3CAPRKDC
Hydrochloric Acid SCHEMBL30042833 0.83 CRBN (0.57) CRBNDDB1IKZF2PIK3CAPRKDC
Hydrochloric Acid SCHEMBL30042846 0.83 CRBN (0.57) CRBNDDB1IKZF2SLC6A4DRD2
SCHEMBL24764790 0.83 DDB1 (0.63) CRBNDDB1IKZF3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260042762-A1 MERTK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-02-12 US disclosed
US-20220356185-A1 MERTK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2022-11-10 US disclosed
US-20220356185-A1 MERTK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2022-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260042762-A1 MERTK DEGRADERS AND USES THEREOF MERTK, CRKL, OSTC CRBN 39/4885DDB1 2712/4885IKZF2 2646/4885
US-20220356185-A1 MERTK DEGRADERS AND USES THEREOF MERTK, ITK, CRKL CRBN 183/4885DDB1 3837/4885IKZF2 1564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.